You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

SERZONE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Serzone patents expire, and what generic alternatives are available?

Serzone is a drug marketed by Bristol Myers Squibb and is included in one NDA.

The generic ingredient in SERZONE is nefazodone hydrochloride. There are four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the nefazodone hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Serzone

A generic version of SERZONE was approved as nefazodone hydrochloride by TEVA on September 16th, 2003.

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for SERZONE?
  • What are the global sales for SERZONE?
  • What is Average Wholesale Price for SERZONE?
Summary for SERZONE
Drug patent expirations by year for SERZONE
Recent Clinical Trials for SERZONE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Boston UniversityPhase 2
Boston Medical CenterPhase 2

See all SERZONE clinical trials

US Patents and Regulatory Information for SERZONE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol Myers Squibb SERZONE nefazodone hydrochloride TABLET;ORAL 020152-001 Dec 22, 1994 DISCN Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Bristol Myers Squibb SERZONE nefazodone hydrochloride TABLET;ORAL 020152-004 Dec 22, 1994 DISCN Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Bristol Myers Squibb SERZONE nefazodone hydrochloride TABLET;ORAL 020152-002 Dec 22, 1994 DISCN Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Bristol Myers Squibb SERZONE nefazodone hydrochloride TABLET;ORAL 020152-003 Dec 22, 1994 DISCN Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Bristol Myers Squibb SERZONE nefazodone hydrochloride TABLET;ORAL 020152-006 Dec 22, 1994 DISCN Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Bristol Myers Squibb SERZONE nefazodone hydrochloride TABLET;ORAL 020152-005 Dec 22, 1994 DISCN Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for SERZONE

International Patents for SERZONE

See the table below for patents covering SERZONE around the world.

Country Patent Number Title Estimated Expiration
Switzerland 663412 1,2,4-TRIAZOL-3-ON-VERBINDUNGEN UND VERFAHREN ZU IHRER HERSTELLUNG. ⤷  Subscribe
Germany 69329942 ⤷  Subscribe
Mexico 9203176 1,2,4-TRIAZOLONAS SUBSTITUIDAS CON FENOXIETILO Y COMPOSICIONES FARMACEUTICAS QUE LAS CONTIENEN. ⤷  Subscribe
South Korea 850000430 ⤷  Subscribe
Luxembourg 84011 ⤷  Subscribe
Switzerland 662562 1,2,4-TRIAZOL-3-ON-VERBINDUNGEN, VERFAHREN ZU IHRER HERSTELLUNG UND SIE ENTHALTENDE PHARMAZEUTISCHE MITTEL. ⤷  Subscribe
>Country >Patent Number >Title >Estimated Expiration

SERZONE Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for SERZONE (Nefazodone)

Introduction

SERZONE, known generically as nefazodone, is an atypical antidepressant that was once widely used for the treatment of depression. Despite its efficacy, the drug's market dynamics and financial trajectory have been significantly impacted by several critical factors, including safety concerns, regulatory actions, and market competition.

Historical Context

Nefazodone was discovered by scientists at Bristol-Myers Squibb (BMS) and was approved for marketing in the United States and Europe in 1994. It was initially marketed under the brand names Serzone in the U.S. and Dutonin in Europe[2].

Efficacy and Clinical Use

SERZONE was indicated for the treatment of depression, with its efficacy established in several controlled clinical trials. These trials demonstrated its effectiveness in reducing symptoms of major depressive disorder and in preventing relapse in patients who had responded to initial treatment[1].

Safety Concerns

One of the most significant factors affecting the market dynamics of SERZONE was the discovery of severe liver toxicity associated with its use. Reports of life-threatening hepatic failure began to emerge in the late 1990s, leading to a black box warning from the FDA in 2002. The incidence of severe liver damage was estimated to be about 1 case per 250,000 to 300,000 patient-years of treatment, resulting in several deaths and liver transplants[1][2].

Regulatory Actions

The safety concerns led to intense regulatory scrutiny. In 2003, Public Citizen filed a petition with the FDA to withdraw the marketing authorization for SERZONE, although the FDA ultimately did not comply with this request. However, the negative publicity and regulatory warnings significantly impacted the drug's sales and reputation[2].

Market Withdrawal

Due to declining sales and the availability of generic versions, BMS announced the discontinuation of SERZONE in the United States in June 2004. The drug was also withdrawn from markets in Europe, Australia, New Zealand, and Canada around the same time[2].

Financial Impact

The financial trajectory of SERZONE was marked by a sharp decline following the reports of liver toxicity. In 2002, despite the addition of a black box warning, the drug still generated $409 million in worldwide sales. However, by 2003, sales had dropped to about $100 million. The introduction of generic versions further eroded the market share of the branded product, leading to its eventual withdrawal from the market[2].

Current Availability

Although the branded version of SERZONE is no longer available, generic versions of nefazodone continue to be manufactured and sold. However, these are not as widely prescribed due to the availability of safer and more effective antidepressant options. In 2020, Teva Pharmaceuticals experienced a shortage of nefazodone due to a raw ingredient shortage, but the drug was made available again in 2021[2].

Market Competition

The antidepressant market is highly competitive, with various classes of drugs such as SSRIs, SNRIs, and atypical antidepressants vying for market share. The rise of safer and more effective treatments, along with increased awareness and reduced stigma around mental health, has driven the growth of the antidepressant market. However, SERZONE's safety issues have made it less competitive compared to other options like sertraline, which have seen sustained growth due to their safety profiles and efficacy[3][5].

Key Takeaways

  • Safety Concerns: Severe liver toxicity associated with SERZONE led to significant regulatory actions and a decline in its use.
  • Market Withdrawal: The drug was withdrawn from major markets due to declining sales and safety issues.
  • Financial Decline: Sales dropped sharply from $409 million in 2002 to $100 million in 2003.
  • Current Status: Generic versions are still available but are not widely prescribed due to safety concerns and competition from other antidepressants.

FAQs

What was the primary reason for the decline in SERZONE's market share?

The primary reason was the discovery of severe liver toxicity associated with its use, leading to regulatory warnings and a decline in prescriptions.

Is SERZONE still available in the market?

Although the branded version is no longer available, generic versions of nefazodone continue to be sold, albeit with limited prescription due to safety concerns.

What were the financial implications of the safety concerns for SERZONE?

The safety concerns led to a significant decline in sales, from $409 million in 2002 to $100 million in 2003, ultimately resulting in the drug's withdrawal from major markets.

How does SERZONE compare to other antidepressants in terms of safety?

SERZONE has a higher risk of severe liver toxicity compared to other commonly used antidepressants, making it less competitive in the market.

What regulatory actions were taken against SERZONE?

The FDA added a black box warning to the drug label in 2002, and Public Citizen filed a petition to withdraw the marketing authorization, although the FDA did not comply with this request.

Sources

  1. RxList: Serzone (Nefazodone): Side Effects, Uses, Dosage, Interactions ...
  2. Wikipedia: Nefazodone
  3. Market.US: Antidepressant Drugs Market to Reach USD 30.5 Billion by 2033
  4. ASPE: Price Trends for Prescription: Pharmaceuticals: 1995-1999
  5. Market Research Intellect: Rising Demand for Sertraline: Market Dynamics, Key Players, and Future Projections

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.